A Clinical Study to Demonstrate Safety and Efficacy of E7777 in Persistent or Recurrent CutaneousT-Cell Lymphoma

Protocol: 
AAAR7696
Phase: 
III

A Clinical Study to Demonstrate Safety and Efficacy of E7777 in Persistent or Recurrent CutaneousT-Cell Lymphoma

The purpose of the Main study is to test the overall effects of E7777 on you
and your illness. It is not known what effect E7777 will have on your
illness or what the side effects will be. This study will look at the
effect E7777 has on your body and your disease. It will also look at how
your body absorbs, distributes, breaks down, and gets rid of the study drug.

Are you Eligible? (Inclusion Criteria)

Are you 18 years or older?
Do you have a diagnosis of Cutaneous T-Cell Lymphoma (mycosis fungoides [MF]
or Sézary Syndrome [SS]), confirmed by skin biopsy, or lymph node, or blood
assessment, of current disease?
Do you have a life expectancy of ≥ 12 months ?
Were you previously treated for Cutaneous T-Cell Lymphoma?

Specialty Area(s)

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States